A Study of Patients With Fabry Disease (US Specific)
Amicus Therapeutics · Fabry Disease
Not applicable
Recruiting
450
2026-07
Industry sponsor intelligence
Amicus TherapeuticsClinical Pipeline.
Lead-sponsor view of Amicus Therapeutics's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 21
- Recruiting
- 2
- Active
- 1
- Completed
- 15
- Results posted
- 12
- Avg enrollment
- 28
Pipeline overview
Programs by phase and activity.
Velocity
Amicus Therapeutics trials by start year
Study start year · indexed snapshot
Development
Trials by phase
19phase labels
Early Phase 10
Phase 15
Phase 26
Phase 38
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Larazotide → | 21 | 5 | 6 | 8 | 0 | 3 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Active, not recruiting
14
2026-07
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Amicus Therapeutics · Fabry Disease
Phase 3
Recruiting
8
2026-06
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
16
2026-02
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
22
2021-11
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
84
2020-12
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 2
Completed
20
2018-12
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
68
2018-11
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 2
Completed
4
2018-10
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 2
Completed
9
2018-10
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
67
2018-10
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 2
Completed
9
2018-10
A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 2
Completed
5
2018-09
Showing 10 of 15 studies
Search sponsor records
All Amicus Therapeutics studies.
This page groups studies where Amicus Therapeutics is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
21 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06906367A Study of Patients With Fabry Disease (US Specific)Jul 10, 2026NCT04020055A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseJul 6, 2026NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsJun 25, 2026NCT04049760Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseaseFeb 5, 2026NCT01476163Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseJul 3, 2025NCT03500094Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)Nov 30, 2021NCT02194985Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseDec 21, 2020NCT01196871Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry DiseaseDec 19, 2018NCT01218659Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseNov 1, 2018NCT00283959A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseOct 31, 2018